Daniel Lochner
CIK 1791187 · Chief Financial Officer · last filed 2026-03-05
Daniel Lochner is a Chief Financial Officer who has filed 22 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing, for TECX, was dated Mar 5, 2026. Across all open-market trades the lifetime net is +$480.4K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.77M
2
22
$480.4K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TECX | Chief Financial Officer | 58,544 | $30.28 | $1.77M | $379.6K | 6 | 2026-03-05 |
| Oyster Point Pharma, Inc. (OYST) Delisted | Chief Financial Officer | 20,236 | $11.17 | $226.0K | $100.8K | 15 | 2023-01-04 |
Recent Filings
22 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-05 | TECX | Grant (A) | +26,500 | $0 | EDGAR |
| 2026-02-11 | TECX | Buy (P) | +6,000 | $129.7K | EDGAR |
| 2026-02-10 | TECX | Tax (F) | −2,077 | -$48.2K | EDGAR |
| 2025-09-29 | TECX | Grant (A) | +5,430 | $0 | EDGAR |
| 2025-02-07 | TECX | Buy (P) | +4,617 | $250.0K | EDGAR |
| 2025-02-06 | TECX | Grant (A) | +18,074 | $0 | EDGAR |
| 2024-06-24 | — | Grant (A) | — | $0 | |
| 2023-01-04 | Oyster Point Pharma, Inc. (OYST) Delisted | Mixed | −77,463 | -$11.0K | EDGAR |
| 2022-12-06 | Oyster Point Pharma, Inc. (OYST) Delisted | Tax (F) | −3,258 | -$36.5K | EDGAR |
| 2022-07-08 | Oyster Point Pharma, Inc. (OYST) Delisted | Grant (A) | — | $0 | EDGAR |